Active site electrostatic effects modulate DBO inhibitor potency against OXA-48 variants
- 1University of Bristol
Abstract
The OXA-48 class D {beta}-lactamase and its variants are clinically concerning through their carbapenemase and cephalosporinase activity. Effective inhibitors are therefore urgently needed. Diazabicyclooctanes (DBOs) are newly introduced non {beta}-lactam based inhibitors, but their potency is affected by mutations, with the more recently developed nacubactam consistently less potent than avibactam, the first DBO, towards OXA-48 variants. This difference is most pronounced for OXA-48 compared to its variants OXA-163 and -405, which contain mutations in the {beta}5-{beta}6 loop and preferentially hydrolyse cephalosporins over carbapenems. Here we use multiscale simulations to uncover the origin of these differences after determining that the second step of DBO acylation is rate-limiting. Using QM/MM MD simulations we show that nacubactam exhibits a consistently higher energy barrier than avibactam for covalent inhibition of OXA-48-like enzymes, a difference attributable to DBO-specific changes in the active site electric field. Simulations of non-covalent complexes further indicate that weaker binding, due to electrostatic repulsion between the positively charged nacubactam tail and Arg214 in the {beta}5-{beta}6 loop, partially explains the lower potency of nacubactam towards OXA-48, compared to OXA-163 and -405. Combining computational predictions of covalent reaction rates and non-covalent binding affinities accurately reproduces the relative order of experimental IC50 values, and predicts potency towards OXA-517, a recently discovered OXA-48 variant capable of hydrolysing many antibiotics. This work provides mechanistic insight into the inhibition of class D {beta}-lactamases and reveals the origins of differential DBO potency towards OXA-48 variants, highlighting how subtle differences between enzymes modulate inhibitory effects.
Related
- Cell-free membrane systems reveal electrostatic control of ion transport in TMEM165 and disease-associated CaCA2 variants
- Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer
- A Dynamics-Informed Machine Learning Framework for Inhibitor Optimization Against Quickly Evolving Targets to Avoid Resistance
- Lipid and Carbohydrate Modifications Enhance Potency of Antisense Oligonucleotides Targeting Oncogenic KRAS
- pSIM: A next generation in vitro mRNA potency assay.
BibTeX
@misc{wang2026active,
title = {{Active site electrostatic effects modulate DBO inhibitor potency against OXA-48 variants}},
author = {D. Wang and R. Chahal and V. H. A. Hirvonen and J. Spencer and M. W. van der Kamp},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.764282},
url = {https://www.biorxiv.org/content/10.64898/2026.11.04.764282v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Active site electrostatic effects modulate DBO inhibitor potency against OXA-48 variants
AU - D. Wang
AU - R. Chahal
AU - V. H. A. Hirvonen
AU - J. Spencer
AU - M. W. van der Kamp
PY - 2026
DA - 2026/11/04
PB - bioRxiv
DO - 10.64898/2026.11.04.764282
UR - https://www.biorxiv.org/content/10.64898/2026.11.04.764282v1
AB - The OXA-48 class D {beta}-lactamase and its variants are clinically concerning through their carbapenemase and cephalosporinase activity. Effective inhibitors are therefore urgently needed. Diazabicyclooctanes (DBOs) are newly introduced non {beta}-lactam based inhibitors, but their potency is affected by mutations, with the more recently developed nacubactam consistently less potent than avibactam, the first DBO, towards OXA-48 variants. This difference is most pronounced for OXA-48 compared to its variants OXA-163 and -405, which contain mutations in the {beta}5-{beta}6 loop and preferentially hydrolyse cephalosporins over carbapenems. Here we use multiscale simulations to uncover the origin of these differences after determining that the second step of DBO acylation is rate-limiting. Using QM/MM MD simulations we show that nacubactam exhibits a consistently higher energy barrier than avibactam for covalent inhibition of OXA-48-like enzymes, a difference attributable to DBO-specific changes in the active site electric field. Simulations of non-covalent complexes further indicate that weaker binding, due to electrostatic repulsion between the positively charged nacubactam tail and Arg214 in the {beta}5-{beta}6 loop, partially explains the lower potency of nacubactam towards OXA-48, compared to OXA-163 and -405. Combining computational predictions of covalent reaction rates and non-covalent binding affinities accurately reproduces the relative order of experimental IC50 values, and predicts potency towards OXA-517, a recently discovered OXA-48 variant capable of hydrolysing many antibiotics. This work provides mechanistic insight into the inhibition of class D {beta}-lactamases and reveals the origins of differential DBO potency towards OXA-48 variants, highlighting how subtle differences between enzymes modulate inhibitory effects.
ER -